Premium
MicroRNA‐18a modulates P53 expression by targeting IRF2 in gastric cancer patients
Author(s) -
Chen YanJie,
Wu Hao,
Zhu JiMin,
Li XiaoDan,
Luo SiWei,
Dong Ling,
Liu TaoTao,
Shen XiZhong
Publication year - 2016
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/jgh.13041
Subject(s) - microrna , cancer research , downregulation and upregulation , medicine , cancer , oncology , pathology , biology , gene , biochemistry
Background and Aim: MicroRNA‐18a (miR‐18a) has been reported to be upregulated in gastric cancer (GC) tissues compared with normal gastric tissues. However, little is known about its prognostic value and biological roles. Methods: In this study, miR‐18a expression in gastric adenocarcinoma (GAC) tissues and adjacent non‐tumor tissues was validated by in situ hybridization, and the predictive values of miR‐18a were explored. The biological roles of miR‐18a and the underlying signal pathway were investigated in GC cell lines. Results: Overexpressed intra‐tumoral miR‐18a was associated with poor survival rate and was an independent prognostic factor for overall survival rate ( P < 0.001) in GC patients. Forced expression of miR‐18a remarkably enhanced cell proliferation, migration, and invasion in GC cells, while inhibition of miR‐18a caused the opposite effects. Further study showed that miR‐18a suppressed the expression of interferon regulatory factor 2 (IRF2) by directly binding to its 3′‐untranslated region. Moreover, miR‐18a expression levels are inversely correlated with IRF2 in human GC tissues. Western blot showed that forced expression of miR‐18a could not only downregulate the expression of IRF2, but also inhibit the expression of P53, suggesting that IRF2 might play as a tumor suppressor by regulating P53 signaling in GC. Conclusion: miR‐18a modulated P53 expression by directly targeting IRF2 and had a high predictive value for prognosis of GAC patients. These results may lead to identification of therapeutic candidates of GC.